文献速递创伤与烧伤重症综合管理与镇静镇痛

中重度创伤性脑损伤试验中GOS与GOSE疗效估计差异的元流行病学分析

A Meta-epidemiologic Analysis of Differences in Treatment-Effect Estimates According to Outcome Scale (GOS vs. GOSE) in Moderate-to-Severe Traumatic Brain Injury Trials.
PubMed 文献 · Neurocrit Care · 2026-08-21
一句话结论中重度TBI试验中,基于GOS的疗效估计大于基于GOSE的试验,两者不可假定完全互换,证据合成时应考虑按量表分层敏感性分析。

78项试验有二分结局(53项GOS,26项GOSE)。校正后结局量表对比ROR为0.880(95%CI 0.679-1.140;I2=33.6%;p=0.326),GOS试验合并OR 1.47(95%CI 1.27-1.69),GOSE试验合并OR 1.07(95%CI 0.90-1.27)。未校正ROR为0.718(p=0.004)。作者结论:GOS试验疗效估计更大,但可能与残留混杂相容,不应因果解读;Meta分析应行量表分层敏感性分析,RCT应标准化结局量表。

要点

  • 中重度TBI试验中,基于GOS的疗效估计大于基于GOSE的试验:GOS合并OR 1.47(95%CI 1.27-1.69) vs GOSE合并OR 1.07(95%CI 0.90-1.27)。
  • 校正后结局量表对比ROR 0.880(95%CI 0.679-1.140;p=0.326),未校正ROR 0.718(p=0.004),方向在敏感性分析中一致(ROR范围0.669-0.886)。
  • GOSE试验偏倚风险各域均较低;试验内阴性对照分析比较二分与序数估计量接近无效。
  • 证据合成时不应假定GOS与GOSE疗效可完全互换,跨量表Meta分析应考虑量表分层敏感性分析。
  • RCT应论证并标准化结局量表的选择与判定。

适用人群与场景

  • 成人中重度创伤性脑损伤(TBI)患者,急性期干预与同期对照比较的随机对照试验。
  • 纳入标准:报告6个月全局功能结局,使用GOS或GOSE。
  • 排除标准:原文未提及。

诊断标准与关键阈值

  • 结局量表:Glasgow Outcome Scale(GOS)或Extended Glasgow Outcome Scale(GOSE),评估6个月全局功能结局。
  • 二分结局用于主要分析。

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 校正后结局量表对比ROR 0.880(95%CI 0.679-1.140;I2=33.6%;p=0.326),校正因素包括发表年份、多中心状态、收入设置、干预类别、终点角色和样本量。
  • GOS试验合并OR 1.47(95%CI 1.27-1.69),GOSE试验合并OR 1.07(95%CI 0.90-1.27)。
  • 未校正ROR 0.718(p=0.004);敏感性、序数子集和结构分析方向一致(ROR范围0.669-0.886)。
  • GOSE试验偏倚风险各域较低;试验内阴性对照分析比较二分与序数估计量接近无效。

证据类型、等级与局限

  • 证据类型:元流行病学分析(基于RCT的二次研究)。
  • 证据等级或推荐强度:原文未提及。
  • 局限:残留的试验间混杂可能解释观察到的差异,不应因果解读;观察性对比,非随机比较GOS与GOSE。

对床旁实践的改变

  • 在证据合成中不应假定GOS与GOSE的疗效估计完全互换。
  • 跨GOS和GOSE量表的Meta分析应考虑按量表分层的敏感性分析。
  • RCT应论证并标准化结局量表(GOS或GOSE)的判定。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

BACKGROUND: Traumatic brain injury (TBI) trials commonly assess global functional outcome using the Glasgow Outcome Scale (GOS) or Extended Glasgow Outcome Scale (GOSE). Because GOS- and GOSE-based trials are often pooled or compared in evidence synthesis, whether treatment-effect estimates differ systematically by outcome scale remains unresolved.

OBJECTIVE: We aim to estimate the between-trial contrast in treatment-effect estimates comparing GOSE-based with GOS-based randomized controlled trials (RCTs) of moderate-to-severe TBI.

METHODS: We conducted a meta-epidemiologic analysis of RCTs comparing acute-phase interventions with a concurrent control in adults with moderate-to-severe TBI and reporting 6-month global functional outcome using GOS or GOSE. Random-effects meta-regression estimated the ratio of odds ratios (ROR) contrasting GOSE- with GOS-based trials, adjusted for publication year, multicenter status, income setting, intervention class, endpoint role, and sample size. Sensitivity, structural, and small-study-effect analyses were prespecified.

RESULTS: Eighty-four RCTs (> 20,000 participants) met eligibility criteria. Dichotomous outcomes were available for 78 trials (53 GOS and 26 GOSE observations). The adjusted outcome-scale contrast was ROR 0.880 [95% confidence interval (CI) 0.679-1.140; I2 = 33.6%; p = 0.326], with larger pooled effects in GOS-based (OR 1.47, 95% CI 1.27-1.69) than GOSE-based trials (OR 1.07, 95% CI 0.90-1.27). The contrast attenuated from an unadjusted ROR of 0.718 (p = 0.004) and remained directionally consistent across sensitivity, ordinal-subset, and structural analyses (ROR range 0.669-0.886). Risk of bias was lower in GOSE-based trials across domains, and a within-trial negative-control analysis comparing binary and ordinal estimators was near null.

CONCLUSIONS: GOS-based TBI trials yielded larger treatment-effect estimates than GOSE-based trials. Although directionally consistent across prespecified analyses, this pattern remained compatible with residual between-trial confounding and should not be interpreted causally. GOS- and GOSE-based treatment effects should not be assumed fully interchangeable in evidence synthesis. Meta-analyses spanning both scales should consider scale-stratified sensitivity analyses, and RCTs should justify and standardize outcome-scale ascertainment.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Raccagni NG, Dotti M, Lightfoot YA, et al. A Meta-epidemiologic Analysis of Differences in Treatment-Effect Estimates According to Outcome Scale (GOS vs. GOSE) in Moderate-to-Severe Traumatic Brain Injury Trials. Neurocrit Care. 2026. PMID: 42625005. doi:10.1007/s12028-026-02634-9

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。